The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.
Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients.
Abstract
Eight patients with refractory ovarian cancer were treated on a pilot protocol of verapamil plus Adriamycin (Adria Laboratories, Columbus, OH). This trial was based on our previous laboratory studies which demonstrated that Adriamycin resistance in human ovarian cancer cell lines could be partially reversed by exposure of the cells to high concentrations of verapamil (3,000 ng/mL). Patients were treated in an intensive care unit with continuous cardiovascular monitoring. The dose of verapamil was escalated in each patient until hypotension or heart block developed, and this dose was maintained for 72 hours. Adriamycin (50 mg/m2) was infused over 24 hours during the second day of the verapamil infusion and verapamil alone was administered on the third day in an effort to block efflux from drug-resistant cells. This intensive approach led to a median plasma verapamil level of 1,273 ng/mL (range, 720 to 2,767). However, the high infusion rates of verapamil (9 micrograms/kg/min) required to achieve these plasma levels produced an unacceptable degree of cardiac toxicity. Two patients developed transient atropine-responsive complete heart block and four patients developed transient congestive heart failure with increases in pulmonary capillary wedge pressure. There was no evidence that the noncardiac toxicities of Adriamycin were enhanced by verapamil. There were no objective responses to therapy. Future studies should use less cardiotoxic calcium channel blockers that can be safely administered to produce the plasma levels required for in vitro sensitization of drug resistant cells.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Anthracycline Antineoplastic Drugs
Young, R. C., Ozols, R. F., & Myers, C. E. (1981) · New England Journal of Medicine · doi:10.1056/nejm198107163050305 · Cited by 793
Self-citationReduced permeability in CHO cells as a mechanism of resistance to colchicine
Ling, V., & Thompson, L. H. (1974) · Journal of Cellular Physiology · doi:10.1002/jcp.1040830114 · Cited by 686
Tsuruo, T., Iida, H., Tsukagoshi, S., & Sakurai, Y. (1982) · PubMed · Cited by 659
Reversal of Adriamycin Resistance by Verapamil in Human Ovarian Cancer
Rogan, A. M., Hamilton, T. C., Young, R. C., Klecker, R. W., & Ozols, R. F. (1984) · Science · doi:10.1126/science.6372095 · Cited by 396
Self-citationYoung, R. C., Chabner, B. A., Hubbard, S. P., Fisher, R. I., Bender, R. A., Anderson, T., Simon, R. M., Canellos, G. P., & DeVita, V. T. (1978) · New England Journal of Medicine · doi:10.1056/nejm197812072992301 · Cited by 318
Self-citationChemotherapy of ovarian cancer
Ozols, R. F. (1998) · Cancer Treatment and Research · doi:10.1007/978-1-4615-5447-9_7 · Cited by 298
Self-citationGreene, R. F., Collins, J. M., Jenkins, J., Speyer, J. L., & Myers, C. E. (1983) · PubMed · Cited by 292
Tsuruo, T., Iida, H., Kitatani, Y., et al. (1984) · PubMed · Cited by 230
Ozols, R. F., Young, R. C., Speyer, J. L., Sugarbaker, P. H., Greene, R. F., Jenkins, J., & Myers, C. E. (1982) · PubMed · Cited by 226
Self-citationRamu, A., Glaubiger, D. L., & FUKS, Z. Y. (1984) · PubMed · Cited by 179
Cited by
Inhibition of the Multidrug Resistance P-Glycoprotein: Time for a Change of Strategy?
Callaghan, R., Luk, F., & Bebawy, M. (2014) · Drug Metabolism and Disposition · doi:10.1124/dmd.113.056176 · Cited by 453
Vaidyanathan, A., Sawers, L., Gannon, A.-L., Chakravarty, P., Scott, A. L., Bray, S. E., Ferguson, M. J., & Smith, G. (2016) · British Journal of Cancer · doi:10.1038/bjc.2016.203 · Cited by 364
Hanssen, K. M., Haber, M., & Fletcher, J. I. (2021) · Drug Resistance Updates · doi:10.1016/j.drup.2021.100795 · Cited by 102
ABC Transporters: Unvalidated Therapeutic Targets in Cancer and the CNS
W. Robey, R., R. Massey, P., Amiri-Kordestani, L., & E. Bates, S. (2010) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/187152010794473957 · Cited by 85
Maiti, C., Parida, S., Kayal, S., Maiti, S., Mandal, M., & Dhara, D. (2018) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.7b18245 · Cited by 75
Metadata
- Authors
- Ozols, R. F., Cunnion, R. E., Klecker, R. W., Hamilton, T. C., Ostchega, Y., Parrillo, J. E., & Young, R. C.
- Venue
- Journal of Clinical Oncology
- Published
- 1987-04
- Volume
- 5
- Issue
- 4
- Pages
- 641-647
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2223026985
- Cited by
- 426
- References
- 14
- FWCI
- 12.67
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. https://app.cochat.ai/papers/10.1200/jco.1987.5.4.641
- The paper
- Ozols, R. F., Cunnion, R. E., Klecker, R. W., Hamilton, T. C., Ostchega, Y., Parrillo, J. E., & Young, R. C. (1987). Verapamil and adriamycin in the treatment of drug-resistant ovarian cancer patients. Journal of Clinical Oncology. https://doi.org/10.1200/jco.1987.5.4.641
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
